Top

Published in:

Open Access 01-03-2011

HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

Authors: Eva A. Operskalski, Andrea Kovacs

Published in: Current HIV/AIDS Reports | Issue 1/2011

Abstract

World-wide, hepatitis C virus (HCV) accounts for approximately 130 million chronic infections, with an overall 3% prevalence. Four to 5 million persons are co-infected with HIV. It is well established that HIV has a negative impact on the natural history of HCV, including a higher rate of viral persistence, increased viral load, and more rapid progression to fibrosis, end-stage liver disease, and death. Whether HCV has a negative impact on HIV disease progression continues to be debated. However, following the introduction of effective combination antiretroviral therapy, the survival of coinfected individuals has significantly improved and HCV-associated diseases have emerged as the most important co-morbidities. In this review, we summarize the newest studies regarding the pathogenesis of HIV/HCV coinfection, including effects of coinfection on HIV disease progression, HCV-associated liver disease, the immune system, kidney and cardiovascular disease, and neurologic status; and effectiveness of current anti-HIV and HCV therapies and proposed new treatment strategies.

Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44(1 Suppl):S6–9.CrossRefPubMed

Thomas DL and Seeff LB: Natural history of hepatitis C. Clin Liver Dis 2005, 9(3):383–98, vi.CrossRefPubMed

Frederick T, Burian P, Terrault N, et al.: Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009, 23(11):915–23.CrossRefPubMed

Tohme RA and Holmberg SD: Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010, 52(4):1497–505.CrossRefPubMed

van de Laar TJ, Paxton WA, Zorgdrager F, et al.: Sexual Transmission of Hepatitis C Virus in Human Immunodeficiency Virus-Negative Men Who Have Sex With Men: A Series of Case Reports. Sex Transm Dis 2010.

Koziel MJ and Peters MG: Viral hepatitis in HIV infection. N Engl J Med 2007, 356(14):1445–54.CrossRefPubMed

Soriano V, Mocroft A, Rockstroh J, et al.: Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198(9):1337–44.CrossRefPubMed

Laskus T, Operskalski EA, Radkowski M, et al.: Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis 2007, 195(1):124–33.CrossRefPubMed

Moreno S, Garcia-Samaniego J, Moreno A, et al.: Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat 2009, 16(4):249–58.CrossRefPubMed

10.

Castera L: Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009, 16(5):300–14.CrossRefPubMed

11.

Sulkowski MS: Management of hepatic complications in HIV-infected persons. J Infect Dis 2008, 197 Suppl 3:S279–93.CrossRefPubMed

12.

Neukam K, Macias J, Mira JA, and Pineda JA: A review of current anti-HCV treatment regimens and possible future strategies. Expert Opin Pharmacother 2009, 10(3):417–33.CrossRefPubMed

13.

Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol 2008, 48(2):353–67.CrossRefPubMed

14.

Webster DP, Klenerman P, Collier J, and Jeffery KJ: Development of novel treatments for hepatitis C. Lancet Infect Dis 2009, 9(2):108–17.CrossRefPubMed

15.

• Franciscus A, (Editor): Hepatitis C treatments in current clinical development. HCV Advocate 2010. This is an annotated tabulated summary of HCV drugs in clinical development.

16.

Rotman Y and Liang TJ: Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009, 83(15):7366–74.CrossRefPubMed

17.

Roe B and Hall WW: Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med 2008, 10:e30.CrossRefPubMed

18.

Kim AY and Chung RT: Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology 2009, 137(3):795–814.CrossRefPubMed

19.

Blackard JT and Sherman KE: HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008, 15(5):323–30.CrossRefPubMed

20.

Martin-Thormeyer EM and Paul RH: Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 2009, 19(2):215–31.CrossRefPubMed

21.

Soriano V, Vispo E, Labarga P, et al.: Viral hepatitis and HIV co-infection. Antiviral Res 2010, 85(1):303–15.CrossRefPubMed

22.

Chen TY, Ding EL, Seage Iii GR, and Kim AY: Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49(10):1605–15.CrossRefPubMed

23.

d’Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al.: Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009, 49(4):612–22.CrossRefPubMed

24.

•• Kovacs A, Karim R, Mack WJ, et al.: Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010, 201(6):823–34. This study showed that HCV-viremic women with HIV co-infection who have high levels of T-cell activation may have increased AIDS risk, and suggested that earlier treatment of HIV and HCV infections may be beneficial.

25.

Kovacs A, Al-Harthi L, Christensen S, et al.: CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008, 197(10):1402–7.CrossRefPubMed

26.

Gonzalez VD, Falconer K, Blom KG, et al.: High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009, 83(21):11407–11.CrossRefPubMed

27.

Korner C, Kramer B, Schulte D, et al.: Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin Sci (Lond) 2009, 116(12):861–70.CrossRef

28.

Potter M, Odueyungbo A, Yang H, et al.: Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010, 24(12):1857–65.CrossRefPubMed

29.

Peters L, Mocroft A, Soriano V, et al.: Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009, 50(5):457–63.CrossRefPubMed

30.

Yacisin K, Maida I, Rios MJ, et al.: Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24(7):935–40.CrossRefPubMed

31.

Al-Harthi L, Voris J, Du W, et al.: Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006, 193(9):1202–10.CrossRefPubMed

32.

•• Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and Adolescents. Department of Health and Human Services. 2009. p. 1–161. These are recent US guidelines for antiretroviral therapy in HIV/HCV co-infection.

33.

Thein HH, Yi Q, Dore GJ, and Krahn MD: Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22(15):1979–91.CrossRefPubMed

34.

Martin-Carbonero L, de Ledinghen V, Moreno A, et al.: Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat 2009, 16(11):790–5.CrossRefPubMed

35.

Maida I, Soriano V, Barreiro P, et al.: Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. AIDS Res Hum Retroviruses 2007, 23(6):801–4.CrossRefPubMed

36.

Smit C, van den Berg C, Geskus R, et al.: Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008, 47(2):221–5.CrossRefPubMed

37.

Sterling RK, Contos MJ, Smith PG, et al.: Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008, 47(4):1118–27.CrossRefPubMed

38.

Machado MV, Oliveira AG, and Cortez-Pinto H: Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010, 52(1):71–8.PubMed

39.

Kuntzen T, Tural C, Li B, et al.: Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008, 22(2):203–10.CrossRefPubMed

40.

Nakamoto N, Kaplan DE, Coleclough J, et al.: Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008, 134(7):1927–37, 1937 e1–2CrossRefPubMed

41.

Vali B, Yue FY, Jones RB, et al.: HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS One 2008, 3(10):e3454.CrossRefPubMed

42.

Balagopal A, Philp FH, Astemborski J, et al.: Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008, 135(1):226–33.CrossRefPubMed

43.

Tuyama AC, Hong F, Saiman Y, et al.: Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010, 52(2):612–22.CrossRefPubMed

44.

Jang JY, Shao R-X, Lin W, et al.: HIV increases HCV-induced hepatocyte apoptosis. Journal of Hepatology In Press, Accepted Manuscript.

45.

Halfon P, Penaranda G, Carrat F, et al.: Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009, 30(1):61–70.CrossRefPubMed

46.

Merchante N, Rivero A, de Los Santos-Gil I, et al.: Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009, 58(12):1654–60CrossRefPubMed

47.

Kirk GD, Astemborski J, Mehta SH, et al.: Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009, 48(7):963–72.CrossRefPubMed

48.

Vergara S, Macias J, Rivero A, et al.: The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007, 45(8):969–74.CrossRefPubMed

49.

Nunes D, Fleming C, Offner G, et al.: Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010, 105(6):1346–53.CrossRefPubMed

50.

Al-Mohri H, Murphy T, Lu Y, et al.: Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007, 44(4):463–9.CrossRefPubMed

51.

Suzman DL, McLaughlin M, Hu Z, et al.: Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS 2008, 22(12):1433–9.CrossRefPubMed

52.

Ghotb A, Noworolski SM, Madden E, et al.: Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr 2010.

53.

Lapinski TW, Parfieniuk A, Rogalska-Plonska M, et al.: Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. Liver Int 2009, 29(8):1158–61.CrossRefPubMed

54.

Reingold J, Wanke C, Kotler D, et al.: Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008, 48(2):142–8.CrossRefPubMed

55.

Marks KM, Clarke RM, Bussel JB, et al.: Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 52(5):595–9.CrossRefPubMed

56.

Wyatt CM, Malvestutto C, Coca SG, et al.: The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008, 22(14):1799–807.CrossRefPubMed

57.

Fischer MJ, Wyatt CM, Gordon K, et al.: Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010, 53(2):222–6.CrossRefPubMed

58.

Izzedine H, Sene D, Cacoub P, et al.: Kidney diseases in HIV/HCV-co-infected patients. AIDS 2009, 23(10):1219–26.CrossRefPubMed

59.

Bedimo R, Westfall AO, Mugavero M, et al.: Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010, 11(7):462–8.PubMed

60.

Castro IF, Micheloud D, Berenguer J, et al.: Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. AIDS 2010.

61.

Letendre S, Paulino AD, Rockenstein E, et al.: Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007, 196(3):361–70.CrossRefPubMed

62.

Vivithanaporn P, Maingat F, Lin LT, et al.: Hepatitis C virus core protein induces neuroimmune activation and potentiates human immunodeficiency virus-1 neurotoxicity. PLoS One 2010, 5(9).

63.

Aronow HA, Weston AJ, Pezeshki BB, and Lazarus TS: Effects of coinfection with HIV and hepatitis C virus on the nervous system. AIDS Read 2008, 18(1):43–8.PubMed

64.

Hinkin CH, Castellon SA, Levine AJ, et al.: Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis 2008, 27(2):11–7.CrossRefPubMed

65.

Ancuta P, Kamat A, Kunstman KJ, et al.: Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008, 3(6):e2516.CrossRefPubMed

66.

Clifford DB, Smurzynski M, Park LS, et al.: Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2009, 73(4):309–14.CrossRefPubMed

67.

Cherry CL, Affandi JS, Brew BJ, et al.: Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology 2010, 74(19):1538–42.CrossRefPubMed

68.

Butt AA, McGinnis K, Rodriguez-Barradas MC, et al.: HIV infection and the risk of diabetes mellitus. AIDS 2009, 23(10):1227–34.CrossRefPubMed

69.

Howard AA, Hoover DR, Anastos K, et al.: The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2010, 54(2):152–9.PubMed

70.

Collin F, Duval X, Le Moing V, et al.: Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009, 23(8):1021–4.CrossRefPubMed

71.

Pascual-Pareja JF, Caminoa A, Larrauri C, et al.: HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS 2009, 23(8):971–5.CrossRefPubMed

72.

Moodie EE, Pant Pai N, and Klein MB: Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 2009, 4(2):e4517.CrossRefPubMed

73.

•• Thompson MA, Aberg JA, Cahn P, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304(3):321–33. These are recent US guidelines for antiretroviral therapy in HIV/HCV co-infection.

74.

Tedaldi E, Peters L, Neuhaus J, et al.: Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008, 47(11):1468–75.CrossRefPubMed

75.

Labarga P, Vispo E, Barreiro P, et al.: Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr 2010, 53(3):364–8.CrossRefPubMed

76.

Labarga P, Soriano V, Vispo ME, et al.: Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196(5):670–6.CrossRefPubMed

77.

Soriano V, Puoti M, Sulkowski M, et al.: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007, 21(9):1073–89.CrossRefPubMed

78.

England K, Thorne C, Pembrey L, and Newell ML: Policies and practices for the clinical management of HIV/HCV coinfected children in Europe: an epidemiological survey. Eur J Pediatr 2009, 168(8):915–7.CrossRefPubMed

79.

Iorio A, Marchesini E, Awad T, and Gluud LL: Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database Syst Rev 2010, (1):CD004888.

80.

Van den Eynde E, Crespo M, Esteban JI, et al.: Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009, 48(8):1152–9.CrossRefPubMed

81.

Sherman KE, Rouster SD, Stanford S, et al.: Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 2010, 201(5):712–9.PubMed

82.

Martin-Carbonero L, Nunez M, Marino A, et al.: Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008, 22(1):15–21.CrossRefPubMed

83.

Opravil M, Sasadeusz J, Cooper DA, et al.: Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008, 47(1):36–49.CrossRefPubMed

84.

Mira JA, Gutierrez-Valencia A, Gil Ide L, et al.: Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis 2009, 49(8):e84–91.

85.

de Felipe B, Leal M, Soriano-Sarabia N, et al.: HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse. J Viral Hepat 2009, 16(1):21–7.CrossRefPubMed

86.

Osinusi A, Rasimas JJ, Bishop R, et al.: HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J Acquir Immune Defic Syndr 2010, 53(3):357–63.CrossRefPubMed

87.

Bhattacharya D, Umbleja T, Carrat F, et al.: Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 2010.

88.

Toma S, Yamashiro T, Arakaki S, et al.: Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha. J Viral Hepat 2009, 16(7):506–12.CrossRefPubMed

89.

Vispo E, Barreiro P, Pineda JA, et al.: Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, 13(3):429–37.PubMed

90.

Amorosa VK, Slim J, Mounzer K, et al.: The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010, 15(1):91–9.CrossRefPubMed

91.

Reiberger T, Kosi L, Maresch J, et al.: Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis 2010, 202(1):156-60.CrossRefPubMed

92.

Bani-Sadr F, Lapidus N, Bedossa P, et al.: Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008, 46(5):768–74.CrossRefPubMed

93.

Price P, Murdoch DM, Agarwal U, et al.: Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009, 22(4):651-63.CrossRefPubMed

94.

Ofotokun I, Smithson SE, Lu C, et al.: Liver enzymes elevation and immune reconstitution among treatment-naive HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 2007, 334(5):334–41.CrossRefPubMed

95.

Cicconi P, Cozzi-Lepri A, Phillips A, et al.: Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007, 21(5):599–606.CrossRefPubMed

96.

Pockros PJ, Nelson D, Godofsky E, et al.: R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008, 48(2):385–97.CrossRefPubMed

97.

Roberts SK, Cooksley G, Dore GJ, et al.: Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008, 48(2):398–406.CrossRefPubMed

98.

Shi ST, Herlihy KJ, Graham JP, et al.: Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009, 53(6):2544–52.CrossRefPubMed

99.

Venkatraman S, Velazquez F, Wu W, et al.: Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem 2009, 52(2):336–46.CrossRefPubMed

100.

Li H, Tatlock J, Linton A, et al.: Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 2009, 52(5):1255–8.CrossRefPubMed

101.

Rodriguez-Torres M: On the cusp of change: new therapeutic modalities for HCV. Ann Hepatol 2010, 9 Suppl:123–31.PubMed

102.

Fowell AJ and Nash KL: Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010, 27(8):512–22.CrossRefPubMed

103.

Poordad F, Lawitz E, Shiffman ML, et al.: Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010, 52(4):1208–15.CrossRefPubMed

104.

Thomson EC, Nastouli E, Main J, et al.: Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009, 23(1):89–93.CrossRefPubMed

105.

Matthews GV, Hellard M, Haber P, et al.: Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009, 48(5):650–8.CrossRefPubMed

106.

Schulze Zur Wiesch J, Pieper D, Stahmer I, et al.: Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis 2009, 49(3):466–72.CrossRefPubMed

Title: HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies
Authors: Eva A. Operskalski
Andrea Kovacs
Publication date: 01-03-2011
Publisher: Current Science Inc.
Published in: Current HIV/AIDS Reports / Issue 1/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-010-0071-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Revisiting Immune Exhaustion During HIV Infection

Coreceptors and HIV-1 Pathogenesis

The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy

Pathogenesis of HIV in the Central Nervous System

Erratum to: Alterations of the B-Cell Response by HIV-1 Replication

The Search for Host Genetic Factors of HIV/AIDS Pathogenesis in the Post-Genome Era: Progress to Date and New Avenues for Discovery

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page